Treatment device

Abstract

A therapeutic device (1) for the treatment of inflammatory and painful human conditions, and for the reconditioning of human neuromuscular and postural conditions, the therapeutic device (1) comprising at least one layered support element (2), the layered support element (2) being formed from a material that is transparent to a reference wavelength of 400 to 990 nm, a first side of the layered support element (2) adapted for contact with the skin of a user, and at least one nanocrystal or mixture of nanocrystals (3) disposed on, incorporated into or dispersed within the layered support element on a second side opposite the first side of the layered support element (2), the nanocrystal or mixture of nanocrystals (3) being capable of emitting photons of the reference wavelength upon exposure to infrared, light or ultraviolet electromagnetic radiation, and comprising a photoluminescent material (4).

Description

[Technical Field]

[0001] The present invention relates to a therapeutic device for painful inflammatory conditions, neuromuscular and postural realignment. [Background technology]

[0002] Innovative technologies and techniques are now known that aim to treat, inter alia, inflammatory and painful conditions or movement disorders, as well as improve posture and proprioception, by integrating and enhancing the effectiveness of traditional and modern therapies for the human body.

[0003] Such a technology is disclosed in document WO2021 / 084424A1, which describes a therapeutic device capable of transmitting photons adapted to the human body. This device enhances proprioception by continuously stimulating areas of imbalance and neuralgia without releasing chemicals, and is an innovative technology for health and well-being based on modern knowledge of biophysics applied to health and well-being.

[0004] The therapeutic device aims to improve movement, help restore joint function, reduce pain caused by improper postural patterns, and correct improper postural patterns to restore energy so that it can be used to enhance overall health.

[0005] The therapeutic device takes the form of small foil elements that are applied to the skin using a patch tape, allowing for the maintenance of postural balance over an extended period of time, functioning in an integrated manner with the effects of the treatment under study.

[0006] The therapeutic device includes at least one layered support element and at least one nanocrystal. The layered support element is formed from a material that is transparent to a reference wavelength between 400 and 990 nm. A first side of the layered support element is intended for contact with human skin. A second side of the layered support element, i.e., the side opposite the first side, has at least one nanocrystal or mixture of nanocrystals disposed thereon, incorporated into the layered support element itself, or dispersed therein. The nanocrystal or mixture of nanocrystals is configured to emit photons of the reference wavelength when stressed by infrared, light, and / or ultraviolet electromagnetic radiation. Summary of the Invention [Problem to be solved by the invention]

[0007] However, the duration of action of the therapeutic device is strictly dependent on the stress of infrared, light or ultraviolet electromagnetic radiation, and once this stress is discontinued, the emission of photons by the nanocrystal or nanocrystal mixture will cease in a short period of time.

[0008] Document EP2383017A1 discloses a phototherapy patch adapted to relieve nociceptive pain in specific body parts by irradiating light. The patch is designed to conform to the shape of the body and includes an active light source that emits light with a wavelength of 430 nm to 475 nm, illuminating the area where the patch is applied.

[0009] Therefore, current technology presents challenges in achieving devices with higher autonomy by significantly extending their operating time and reducing their dependence on stresses caused by external electromagnetic radiation. [Means for solving the problem]

[0010] The present invention aims to overcome the limitations of current technology by means of a device as described above, which further comprises a photoluminescent material capable of absorbing photons under the influence of electromagnetic radiation and re-emitting photons even after the stress of the electromagnetic radiation has ceased.

[0011] The photoluminescent material absorbs photons under the influence of electromagnetic radiation and then re-emits them, thereby extending the action of the therapeutic device even after the external electromagnetic radiation stress has ceased. That is, the photons absorbed by the photoluminescent material and resulting from the electromagnetic radiation are then re-emitted by the photoluminescent material itself, and these photons constitute an electromagnetic stress on the nanocrystal or mixture of nanocrystals. Thus, the nanocrystals stressed in this way will emit photons of the reference wavelength even after the external electromagnetic radiation has ceased.

[0012] In a preferred embodiment, the treatment device is passive, ie, does not have a light source.

[0013] In one embodiment, a layer of said photoluminescent material is provided.

[0014] This allows devices to be easily constructed from independent layers, each with its own functionality.

[0015] Alternatively or in combination with the above configurations, the following configurations may also be used: the photoluminescent material may be mixed or incorporated within the layer elements and / or within the mixture of nanocrystals.

[0016] According to a further embodiment, the nanocrystals or mixture of nanocrystals form an active layer, and a layer of photoluminescent material is interposed between the layer element and said active layer.

[0017] By having the photoluminescent material in direct contact with the active layer containing nanocrystals or a mixture of nanocrystals, the effect of the electromagnetic stress provided by the layer of photoluminescent material can be optimized.

[0018] In one embodiment, the thickness of the layer of photoluminescent material is in the range of 50 micrometers to 100 micrometers (particularly 75 micrometers to 85 micrometers).

[0019] According to one embodiment, the photoluminescent material comprises a powdered fluorescent pigment diluted in ink.

[0020] In one embodiment, the fluorescent pigment is diluted in the ink to a concentration of 20% to 80%.

[0021] According to a particularly advantageous embodiment, the photoluminescent material comprises strontium aluminate.

[0022] This material has the advantage that it allows a long-lasting photoluminescence effect, does not have an unpleasant odor, and does not react adversely with other elements such as adhesives used to fix the layers. [Brief explanation of the drawings]

[0023] The various features and advantages of the present invention may be more readily understood by reference to the following exemplary embodiments when taken in conjunction with the accompanying drawings. [Figure 1] 1 is a schematic diagram of a treatment device according to a first embodiment. [Figure 2] FIG. 10 is a schematic diagram of a treatment device according to a second embodiment. DETAILED DESCRIPTION OF THE INVENTION

[0024] 1 shows an embodiment of a treatment device 1 for human inflammatory and painful conditions, human neuromuscular and postural realignment according to the present invention. The illustration is for illustrative purposes only and does not represent the actual scale of the device.

[0025] As shown in Figure 1, the treatment device 1 includes a layered support element 2 made of a material that is transparent to wavelengths ranging from 400 nm to 990 nm. A first side of the layered support element 2 is adapted for contact with human skin.

[0026] The layered support element 2 is made of a material that is transparent to at least one of infrared, light, and ultraviolet electromagnetic radiation. This material is a polymer that can bond with the human epidermis and is impermeable and inert to sweat released from the skin. This material is flexible and can follow the movements and deformations of the epidermis without peeling off from the human epidermis. Preferably, the foil element 2 has a thickness between 0.05 mm and 2 mm, more preferably between 0.1 mm and 1 mm, so that it can suitably follow the deformations of the epidermis.

[0027] At least one nanocrystal or a mixture of nanocrystals 3 is disposed on a second side of the layered support element 2 opposite the first side in contact with the epidermis. The nanocrystal or mixture of nanocrystals is capable of emitting photons of a reference wavelength when stressed by infrared, light or ultraviolet electromagnetic radiation.

[0028] The nanocrystal or mixture of nanocrystals may be incorporated into or dispersed in the layered support element 2. In this case, at least one nanocrystal or mixture of nanocrystals 3 is arranged so as to be dispersed over most of the side on which it is arranged, like a coating, with a thickness of 0.001 mm to 1 mm to reduce the effect of overlapping nanocrystals and use the entire side for the high transmission efficiency of electromagnetic radiation as described above.

[0029] At least one nanocrystal or mixture of nanocrystals 3 as described above is arranged on the layered support element 2 in discrete zones to concentrate the flow of electromagnetic radiation in a delimited area, with sufficient strength to be received through the layered support element 2 having a thickness of 0.005 mm to 1 mm.

[0030] Preferably, the mixture of nanocrystals is disposed on the layered support element 2 or is incorporated or dispersed within the layered support element 2 itself, with a density of 1 mg / cm2 to 6 mg / cm2 and capable of emitting photons at the reference wavelength.

[0031] Alternatively or in combination with the above, at least one nanocrystal or a mixture of nanocrystals may be included in a separate layer to form the active layer 3 . The nanocrystal or mixture of nanocrystals preferably comprises one or more of the following quantum dots:

[0032] - graphene quantum dots, code 900708, or quantum dots with the following fluorescence properties: λex 350 nm; λem 445 nm, FWHM 65 nm, quantum yield >65%; Blue-emitting graphene quantum dots, code 900726, or quantum dots with a fluorescence equivalent to the following: λex 350 nm; λem 445 nm + 10 nm, FWHM 75 nm, quantum yield > 20% - Cyan-emitting graphene quantum dots, code 900707, or quantum dots with fluorescence corresponding to the following values: λem 475nm-495nm, FWHM 70nm, quantum yield >17% - Aqua green emitting graphene quantum dots, code 900712, or quantum dots exhibiting the following fluorescence: λex 485 nm; λem 530 nm + 10 nm, FWHM 80 nm, quantum yield > 17%; - perovskite quantum dots coated with oleic acid and oleylamine, code 900747, or quantum dots with fluorescence corresponding to approximately the following wavelength: λem 480nm; - carboxyl-functionalized CdTe core type quantum dots, code 777978, or quantum dots exhibiting fluorescence corresponding to: λ em 710 nm, quantum yield >15%; - oleic acid functionalized CdS / ZnS core-shell type quantum dots, code 900286, or quantum dots exhibiting fluorescence corresponding to: λmax 385 nm λem 400 nm±10 nm, quantum yield >50%; - oleic acid functionalized CdS / ZnS core-shell type quantum dots, code 900283, or quantum dots exhibiting a fluorescence corresponding approximately to: λmax 405 nm λem 425 nm±10 nm; Nanocrystals or mixtures of nanocrystals can reach and produce the same wavelengths as ULLLT (ultra low power laser therapy), but at a much weaker intensity.

[0033] The device further comprises a photoluminescent material 4, preferably provided as a photoluminescent layer 4 separate from other components of the device. Alternatively, or in combination, the photoluminescent material 4 can be mixed with or incorporated into at least one of the layered support element and the mixture of nanocrystals.

[0034] Preferably, a layer of photoluminescent material 4 is interposed between the layered support element 2 and the above-mentioned active layer 3 and has a thickness of 50 to 100 micrometers, in particular 75 to 85 micrometers.

[0035] Preferably, the photoluminescent material 4 comprises a powdered fluorescent pigment diluted in ink, particularly in a proportion between 20% and 80%.

[0036] In a preferred embodiment, the photoluminescent material 4 comprises strontium aluminate, which is particularly advantageous because a photoluminescent layer of the above thickness comprising strontium aluminate will absorb photons, particularly ultraviolet light, to a maximum charge state within minutes and emit photoluminescence with a duration of up to 24 hours.

[0037] Other rare earth elements or other suitable photoluminescent materials, such as barium titanate, zinc sulfate, etc., may be used in place of or in combination with the strontium aluminate described above.

[0038] The photoluminescent layer 4 can be provided in a variety of emitting colors, such as yellow-green, green, blue-green, purple, orange, etc.

[0039] 2 shows a second embodiment in which a second layer element 5 is provided to protect and confine the photoluminescent layer 3. The second layer element 5 is made of a material that is transparent to radiation in the infrared, visible or ultraviolet spectrum, so that external radiation passing through the second layer element 5 charges the photoluminescent layer 4 and excites the mixture of nanocrystals 3 described above to emit radiation of the frequency of interest.

[0040] The layered support element 2 and the second protective and confining layered element 5 confine the nanocrystal or mixture of nanocrystals 3 between them and protect the nanocrystal or mixture of nanocrystals from external factors or mechanical stresses that may lead to damage.

[0041] The second layer element 5 has the same extent as the layer support element 2 and is associated with it so that its side faces the layer support element 2 and leans against it, holding and sealing the nanocrystals or mixture of nanocrystals 3 and the photoluminescent layer 4.

[0042] The second layer element 5 is preferably constructed from a protective transparent ink or film of polymer material, which reduces the overall thickness of the device and improves its wearability.

[0043] The mixture of nanocrystals 3 may be diluted in an ink so that it can be printed directly on the facing sides of the laminar support element 2 and / or the second protective laminar element 5. It is also possible to dilute the pigment of the photoluminescent material 3 in the same ink.

[0044] The wearable therapeutic device provides great activity by using nanocrystals or a mixture of nanocrystals in a ratio of 95% to 20% depending on the type of nanocrystal used and the target frequency of therapeutic radiation, and the amount of photons emitted by the device can be calibrated, redefined, and administered depending on the patient's needs and the stimulation desired.

[0045] It is desirable for the ink to be transparent so that only the adhesive and ink properties act within the dispersion medium and all emitted photons and incident radiation can reach the nanocrystal or nanocrystal mixture 3 with minimal attenuation.

[0046] The overall thickness of the treatment device is minimized to maintain high elasticity and accommodate the surface stresses of the dermis without cracking, breaking or tearing.

[0047] The interconnection of the dermis and the laminar support element 2 and / or the second laminar element 5 can be achieved by means of a flexible double-sided adhesive material.

[0048] The device is nearly transparent and adheres to the skin, allowing it to be placed close to primary and secondary endings, tendons, muscles, dermatomes, and nerve endings, aiding in neuromuscular and postural coordination and providing visible reddening of the skin.

Claims

1. A therapeutic device (1) for human pathologies involving inflammation and pain, human neuromuscular and postural realignment, comprising: at least one laminar support element (2), The layered support element (2) is made of a material that is transparent for a reference wavelength of 400 to 990 nm, a first side of the layered support element (2) adapted for contact with the person's skin; At least one nanocrystal or a mixture of nanocrystals (3) is disposed on a second side of the lamellar support element (2) opposite the first side, either incorporated into the lamellar element itself or dispersed therein; the nanocrystal or mixture of nanocrystals is configured to emit photons of the reference wavelength when stressed by at least one of infrared, light, and ultraviolet electromagnetic radiation; A therapeutic device comprising a photoluminescent material (4) capable of absorbing photons under the influence of said electromagnetic radiation and re-emitting the absorbed photons even after the stress of said electromagnetic radiation has ceased.

2. Therapeutic device according to claim 1, wherein the device is passive, i.e. does not have a light source.

3. 3. The treatment device according to claim 1 or 2, wherein said layer of photoluminescent material (4) is provided.

4. The therapeutic device of claim 3, wherein the nanocrystals or the mixture of nanocrystals form an active layer (3) arranged in contact with the layered support element (2), and the layer of photoluminescent material (4) is arranged in contact with the active layer (3) on the side opposite to the side in contact with the layered support element (2).

5. Therapeutic device according to any one of claims 1 to 4, wherein the layer of photoluminescent material (4) has a thickness of 50 to 100 micrometers.

6. 6. The treatment device of any one of claims 1 to 5, wherein the photoluminescent material (4) comprises a powdered fluorescent pigment diluted in ink.

7. 5. The treatment device according to claim 4, wherein the powdered fluorescent pigment is diluted in the ink to a ratio of 20% to 80%.

8. Therapeutic device according to any one of claims 1 to 7, wherein the photoluminescent material (4) comprises strontium aluminate.

Images